Joxcy 250 Tablet contains Cefuroxime 250 mg, a second-generation cephalosporin antibiotic effective against a broad spectrum of bacterial infections. Cefuroxime acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death, thereby exhibiting bactericidal activity. Joxcy 250 is indicated for the treatment of various infections caused by susceptible strains of bacteria, including respiratory tract infections such as bronchitis and pneumonia, urinary tract infections, skin and soft tissue infections, and uncomplicated gonorrhea. It is also employed in the management of Lyme disease and certain surgical prophylaxis cases. The tablet formulation ensures convenient oral administration with good bioavailability. Dosage and duration of therapy should be determined based on the severity of infection, patient age, renal function, and clinical response. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypersensitivity reactions in susceptible individuals. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Renal impairment necessitates dose adjustment to prevent accumulation and toxicity. Joxcy 250 should be used under medical supervision, with adherence to prescribed dosage to minimize the risk of resistance development and ensure therapeutic efficacy.